- Home
- SG vs ARVN Comparison
SG vs ARVN Comparison
Compare SG & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SG | ARVN |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 797.8M | 781.0M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SG | ARVN |
|---|---|---|
| Price | $8.22 | $12.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 23 |
| Target Price | $15.36 | ★ $18.14 |
| AVG Volume (30 Days) | ★ 4.1M | 806.8K |
| Earning Date | 02-25-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $685,184,000.00 | $312,300,000.00 |
| Revenue This Year | $4.12 | $11.17 |
| Revenue Next Year | $10.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.43 | ★ 93.86 |
| 52 Week Low | $5.14 | $5.90 |
| 52 Week High | $35.16 | $20.38 |
Technical Indicators
Market Signals| Indicator | SG | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 69.34 | 52.47 |
| Support Level | $7.35 | $11.76 |
| Resistance Level | $7.96 | $12.79 |
| Average True Range (ATR) | 0.45 | 0.53 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 95.74 | 62.98 |
Price Performance
Historical ComparisonAbout SG Sweetgreen Inc.
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.